Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implantable pumps. Recent progress and anticipated future advances.

H Buchwald1, T D Rohde

  • 1Department of Surgery, University of Minnesota, Minneapolis 55455.

ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|October 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IFSO Worldwide Survey 2016: Primary, Endoluminal, and Revisional Procedures.

Obesity surgery·2018
Same author

Erratum to: Bariatric Surgery and Endoluminal Procedures: IFSO Worldwide Survey 2014.

Obesity surgery·2017
Same author

Bariatric Surgery and Endoluminal Procedures: IFSO Worldwide Survey 2014.

Obesity surgery·2017
Same author

Reply to Letter to the Editor: Bariatric Surgery Worldwide 2013 Reveals a Rise in Mini-Gastric Bypass.

Obesity surgery·2015
Same author

Bariatric Surgery Worldwide 2013.

Obesity surgery·2015
Same author

Systematic review and meta-analysis of medium-term outcomes after banded Roux-en-Y gastric bypass.

Obesity surgery·2014
Same journal

Machine Learning Prediction of Pediatric In-Hospital Survival Before Extracorporeal Membrane Oxygenation Cannulation.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Erratum: Safety and Efficacy of Stored Wet-Preprimed Extracorporeal Membrane Oxygenation Circuits: A Scoping Review.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Case Series of Extracorporeal Cardiopulmonary Resuscitation for Refractory Cardiopulmonary Arrest After Cardiac Surgery.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Association Between Veno-Venous Extracorporeal Membrane Oxygenation and Right Ventricular Dysfunction in Acute Respiratory Distress Syndrome Patients: A Multicenter Retrospective Propensity-Matched Study.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Prolonged Mechanical Circulatory Support of Neonatal Biventricular Failure via Single Ventricle Conversion With Ventricular Assist Device.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Redefining Limits: Extracorporeal Cardiopulmonary Resuscitation in Adult Thrombotic Thrombocytopenic Purpura.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
See all related articles

Implantable pumps, though not yet a fully artificial beta-cell, are advancing. Programmable insulin pumps are in trials, while other implantable pumps treat pain, cancer, and infections.

Area of Science:

  • Biomedical Engineering
  • Drug Delivery Systems
  • Medical Devices

Background:

  • The field of implantable pumps has existed for over two decades.
  • The initial objective of a completely artificial beta-cell has not yet been achieved.

Purpose of the Study:

  • To review the current status and applications of implantable pump technology.
  • To identify challenges and limitations in the development and commercialization of these devices.

Main Methods:

  • Review of existing literature and clinical applications of implantable pumps.
  • Analysis of the regulatory landscape for implantable drug delivery devices.

Main Results:

  • Programmable insulin pumps, lacking only a glucose sensor, are in US clinical trials and available in Europe.

Related Experiment Videos

  • Implantable pumps are clinically used in the US for pain, spasticity, cancer, and osteomyelitis.
  • Limited commercial availability of potential applications is attributed to pharmaceutical industry practices and complex regulatory processes.

    • Conclusions:

    • Implantable pump technology has progressed significantly, with programmable insulin pumps nearing a key milestone.
    • Barriers to broader adoption include the traditional approach of drug companies to parenteral applications and the intricate regulatory pathway involving both drug and device approvals.